期刊文献+

多发性骨髓瘤侧群细胞的研究进展 被引量:2

Research Advances of Side Population Cells in Multiple Myeloma
下载PDF
导出
摘要 侧群细胞具有高致瘤性、自我更新、多向分化和耐药的潜能。这些特性与肿瘤干细胞相似,因此侧群细胞渐渐成为研究肿瘤干细胞的切入点,为进一步研究肿瘤干细胞的生物学功能和分子机制奠定了基础。多发性骨髓瘤(multiple myeloma,MM)病人及其细胞系中均可以检测到侧群细胞,通过流式细胞仪加以分选,对其致瘤性,细胞周期,分化潜能,表面标记和耐药性进行了研究,更深入地了解多发性骨髓瘤的发病机制,并应用于临床早期诊断,为深入研究多发性骨髓瘤的治疗手段提供新的思路。本文将就多发性骨髓瘤侧群细胞的研究进展进行总结。 Side population cells have high tumorigenicity, self-renew al, and multi-directional differentiation potential,as w ell as chemotherapy resistance. All these characterristics of side population cells are similar to that of the tumor stem cells,so the side population cells gradually have become the point of penetration for the study of tumor stem cells,thus to lay a foundation to further explore the biological function and molecular mechanism of tumor stem cells.The patients w ith multiple myeloma and almost all M M cell lines w ere detected in the side population cells. The tumorigenicity,cell cycle,differentiation potential,surface markers and drug resistance of side population cells w ere studied by cell sorting w ith flow cytometry. The pathogenesis of multiple myeloma,and application to clinical diagnosis at the early stage all w ere understood deeply,so as to provide new ideas for further research on treatment. In this review,the research progress of side population cells in multiple myeloma is briefly summarized.
作者 王蕾 李艳
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2017年第4期1250-1254,共5页 Journal of Experimental Hematology
基金 辽宁省科技厅科学技术计划项目(2013021031)
关键词 多发性骨髓瘤 侧群细胞 细胞周期 multiple myeloma side population cell cycle
  • 相关文献

参考文献7

二级参考文献169

  • 1尹美珍,李世普,袁琳,戴红莲.小鼠腹腔巨噬细胞的分离培养与鉴定[J].武汉大学学报(医学版),2006,27(2):203-205. 被引量:36
  • 2Feng Li,Benjamin Tiede,Joan Massague,Yibin Kang.Beyond tumorigenesis: cancer stem cells in metastasis[J].Cell Research,2007,17(1):3-14. 被引量:86
  • 3Carson CC, 3rd. Carcinoma of the prostate: overview of the most common malignancy in men. N C MedJ 2006; 67:122- 127.
  • 4Shaw GL, Wilson P, Cuzick J, et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU lnt 2007; 99:1056-1065.
  • 5Shaw G, Prowse DM. Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling. Cancer Cell Int 2008; 8:3.
  • 6Petryiak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520.
  • 7Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003; 88:2972-2982.
  • 8Lawson DA, Witte ON. Stem cells in prostate cancer initiation and progression. J Clin Invest 2007; 117:2044-2050.
  • 9Verhagen AP, Ramaekers FC, Aalders TW, et al. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 1992; 52:6182-6187.
  • 10English HF, Santen RJ, Isaacs JT. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 1987; 11:229-242.

共引文献62

同被引文献11

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部